PI Health Sciences Netherlands B.V

What PI Health Sciences Netherlands B.V does

PI Health Sciences Netherlands B.V is the Dutch holding entity for the CRDMO (Contract Research, Development, and Manufacturing Organization) operations of PI Industries Ltd's pharmaceutical arm. The operating company, PI Health Sciences Limited (India), is a wholly-owned subsidiary of publicly listed PI Industries Ltd (NSE: PIIND) and operates as an integrated drug discovery, development, and manufacturing platform serving 25+ global pharmaceutical and biotech innovators. Its service stack spans Integrated Drug Discovery, AI & Computational Chemistry, Discovery Chemistry, Discovery Biology, DMPK, and Preclinical Services on the discovery side, and Process R&D, Analytical Services, Salt/Polymorph Screening, Clinical Development, and preclinical/clinical/commercial Supply on the CMC side. The platform is differentiated by enabling-technology capabilities including flow chemistry (automated pilot plant, hazardous reaction capability including n-BuLi and nitration, demonstrated 8-10 MT/day output), a Center of Excellence in Biotechnology and Biocatalysis (whole-cell and cell-free biocatalysis, fermentation up to 200L), AI-integrated computational drug design (Chemistry42, EVOLVE, AlphaFold, DiffDock, Boltz2), and a Targeted Protein Degradation modality platform spanning PROTAC, LYTAC, Molecular Glues, and AUTAC. Manufacturing is conducted in India (Jaipur for preclinical supply, Hyderabad R&D with ISO 14001 and ISO 45001 certifications) and Italy (Lodi/Milan for clinical phases 1-3 and commercial API supply, including OEB4 high-potency handling), with Udaipur as registered office.

The business model is professional services delivered through quote-based, multi-year enterprise contracts with global pharma and biotech clients, supported by a direct enterprise sales motion and a marketing mix spanning industry events (BIO International Convention, BOS Basel, ChemOutsourcing, Contract Pharma), content marketing, and social channels. Revenue is generated across the full drug-development lifecycle from discovery through commercial API manufacturing, with acquisition-fueled expansion: PI Industries funded the April 2023 acquisitions of Therachem Research Medilab (USD 50 million, India/US) and Italy-based Archimica S.p.A. (EUR 34.2 million) for combined consideration of approximately €84.4 million via QIP proceeds, materially expanding US and European footprint and bringing established API and CDMO operations in-house. In May 2025, the company implemented Cresset's Torx Software for cloud-based DMTA cycle management and secured dual ISO certifications at its Hyderabad site, signaling continued investment in digital and regulatory infrastructure to support enterprise-grade pharma clients.

Name

PI Health Sciences Netherlands B.V

Legal name

PI Health Sciences Limited

Website

https://pihealthsciences.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

501–1,000 employees

Short description

PI Health Sciences is an integrated CRDMO that delivers drug discovery, development, and manufacturing services to 25+ global pharmaceutical and biotech innovators, operating manufacturing in India and Italy with enabling technologies in flow chemistry, biocatalysis, AI computational chemistry, and targeted protein degradation modalities.

Ownership category

akta.pro rank

Product category

Pharmaceutical CRDMO Services

NAICS

Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

akta.pro secondary industries

Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), Solid-State Chemistry & Preformulation (Polymorph/Crystallization) (HLAGAHAI)

Keywords

• Contract research organization
• Drug discovery services
• Pharmaceutical manufacturing
• Flow chemistry services
• Biocatalysis solutions

Headquarters

HQ city

Netherlands

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. CRDMO Services Revenue: PI Health Sciences operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) generating revenue through integrated service contracts spanning drug discovery, development, and commercial manufacturing. Services are delivered through flexible business models with co-located, integrated teams serving global pharmaceutical and biotech innovators.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

PI Health Sciences operates as an integrated CRDMO (Contract Research, Development, and Manufacturing Organization) providing end-to-end pharmaceutical services from drug discovery through commercial manufacturing. The company offers discovery solutions (integrated drug discovery, chemistry, biology, DMPK, preclinical), CMC/development solutions (process R&D, analytical services, clinical development), and manufacturing supply services (preclinical, clinical, and commercial scale) at facilities in India and Italy. It enables these services through proprietary enabling technologies including flow chemistry, biocatalysis, and targeted protein degradation (TPD) modalities such as PROTAC, LYTAC, AUTAC, and molecular glues.

Product overview

PI Health Sciences operates as an integrated CRDMO (Contract Research, Development, and Manufacturing Organization) providing end-to-end pharmaceutical services from discovery through commercial manufacturing. The platform combines Discovery Solutions (Integrated Drug Discovery, AI & Computational Chemistry, Discovery Chemistry, Discovery Biology, DMPK Services, and Preclinical Services) with CMC Solutions (Process R&D, Analytical Services, Salt/Polymorph Screening, Clinical Development, and Manufacturing Supply at preclinical, clinical, and commercial scales), Enabled by proprietary technologies including Flow Chemistry, Biocatalysis, and TPD modalities (AUTAC, Molecular Glues, LYTAC, PROTAC).

Differentiator

Problem solved

Functional benefit

Brands

• Center of Excellence in Biotechnology and Biocatalysis: Dedicated biotechnology and biocatalysis center providing end-to-end enzyme services from gene discovery to large-scale bioprocess production.
• Flow Chemistry Platform

Products and services

• Integrated Drug Discovery (IDD) Fully integrated drug discovery combining synthetic and medicinal chemistry, biology, and AI technologies with co-located teams for preclinical candidates and IND-enabled programs, serving pharmaceutical and biotech innovators.
• AI & Computational Chemistry Advanced computational intelligence and AI-driven drug design using physics-based modeling, structure prediction, generative chemistry, and virtual screening to accelerate molecule design and optimization for drug discovery programs.
• Discovery Chemistry Chemistry-led molecular design and synthesis services including in-silico design, medicinal chemistry, synthetic chemistry, PROTAC chemistry, carbohydrate chemistry, and custom chemistry libraries for hit-to-lead programs.
• Discovery Biology Comprehensive discovery biology solutions for target validation, biochemical and cellular screening, ADME, pharmacokinetics profiling, and in vivo efficacy supported by state-of-the-art infrastructure.
• DMPK Services In-vitro ADME and DMPK services including metabolic stability, permeability, drug-drug interaction assessment, in vivo pharmacokinetics, metabolite identification, and PBPK/popPK modeling for drug discovery and development.
• Preclinical Services Integrated preclinical research including GLP-compliant toxicology, translational biology, PK/PD studies, biomarker analysis, human dose projection, and regulatory submission support for IND and CTA readiness.
• Process R&D Services Phase-appropriate process R&D from early phase development to commercial scale with focus on process optimization, validation, GMP/non-GMP scale-up, and regulatory compliance.
• Analytical Services Advanced analytical method development, validation, and testing including genotoxic impurity analysis, stability studies, potent compound analysis, trace metal testing, and regulatory compliance support.
• Salt and Polymorph Screening Services Solid-state characterization and screening for API optimization including rational counterion selection, high-throughput salt screening, thermodynamic polymorph mapping, and IP expansion for lifecycle management.
• Clinical Development Services Clinical development support services for phase 1-3 programs including study design, regulatory strategy, and seamless transition from development to manufacturing.
• Flow Chemistry Services Continuous manufacturing through advanced flow reactors and automated pilot plants with real-time monitoring and PAT tools for improved process safety, efficiency, and scalability up to 8-10 MT per day.
• Biocatalysis Services End-to-end biocatalysis services from gene discovery through enzyme development, strain engineering, and large-scale bioprocess production for sustainable, eco-efficient manufacturing processes.
• TPD (Targeted Protein Degradation) Platform New modalities platform including AUTAC, Molecular Glues, LYTAC, and PROTAC technologies for targeted protein degradation approaches in drug discovery.
• Preclinical Supply Services Scalable preclinical manufacturing at Jaipur site with advanced reactors, rigorous quality certifications, and precise temperature and pressure control capabilities.
• Clinical Supply Services Reliable clinical supply across phases 1-3 at Lodi, Milan site with scalable manufacturing, advanced reactors, and specialized capabilities for APIs and anti-cancer products.
• Commercial Supply Services Large-scale commercial API manufacturing including deacylated phospholipid production, cytostatic nucleosides, chromatographic purification, and OEB4 potency handling.
• API Portfolio Manufacturing Active Pharmaceutical Ingredient portfolio manufacturing services spanning discovery through commercial scale with facilities in India and Italy.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• CressetcoreTechnology or Integration · 15 May 2025Strategic collaboration to implement Torx Software, a cloud-based DMTA (design-make-test-analyze) platform for small molecule drug discovery. Torx enables seamless coordination of molecule design, synthesis, testing, and data analysis in an integrated digital environment.
• PI Industries Ltd (Parent)coreOthers · 28 April 2023PI Health Sciences is a wholly owned subsidiary of PI Industries Ltd, India's leading agri sciences and life sciences company. Parent company funded CDMO acquisitions (Therachem and Archimica) through QIP proceeds.
• CodexissupportingTechnology or IntegrationCommercial enzyme supplier providing keto-reductase enzymes (24 enzymes) for biocatalysis services
• SyncozymessupportingTechnology or IntegrationCommercial supplier of nitro reductases (12 enzymes) for biocatalysis services

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Syngene International: Indian-listed integrated CRO/CDMO offering discovery, development, and manufacturing services to global pharma and biotech. Closest direct peer given shared India base, integrated service model, and similar enterprise customer targeting.
• Aragen Life Sciences: India-headquartered CRDMO providing drug discovery, development, and contract manufacturing. Comparable scale, service breadth, and customer base; competes head-to-head for mid-pharma and biotech outsourcing mandates.
• Sai Life Sciences: India-based CRO/CDMO offering discovery, CMC, and API manufacturing services. Direct competitor for discovery chemistry and small-molecule development programs out of India.
• Piramal Pharma Solutions: Global CDMO arm of Piramal Group offering API, formulation, and biologics services across India, North America, and Europe. Comparable in geographic spread and integrated CDMO positioning.
• Jubilant Pharmova: India-based pharma services company providing CDMO, generics, and radiopharma services. Direct peer in India-headquartered CDMO space with similar enterprise pharma customer base.
• Curia (formerly Albany Molecular Research): US-headquartered CDMO offering API development, manufacturing, and drug product services. Comparable mid-tier CRDMO scope with discovery-through-commercial capability.

Broad incumbents

• Lonza Group: Global CDMO leader offering API, biologics, and cell & gene services. Sets the benchmark for CRDMO scale, regulatory track record, and pharma relationships; relevant competitive context for any new commercial-scale wins.
• Catalent: Global CDMO with broad capabilities across softgel, biologics, and clinical supply. Comparable service breadth but at materially larger scale; defines the upper bound of what PI Health Sciences must compete against for enterprise contracts.
• WuXi AppTec: China-headquartered global CRDMO with discovery, development, and manufacturing services across small and large molecules. Most direct global benchmark for integrated CRDMO model though at materially larger scale.

Regional players

• Divi's Laboratories: India-headquartered API manufacturer with global pharma customers. Comparable India-based manufacturing scale and API expertise, though focused on generic APIs rather than CRDMO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PIHealthSc24325
• Facebookfacebook.com/share/1CqTbYy478
• LinkedInlinkedin.com/company/pi-health-sciences-781666220
• Instagraminstagram.com/pihealthsciencesofficial

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PI Health Sciences Netherlands B.V